Pancreatic Cancer Disparities among Gender, Race, and Ethnicity: The PRECEDE Consortium Outcomes and Impact.

The Pancreatic Cancer Early Detection (PRECEDE) Consortium was launched internationally to assess the surveillance of high-risk individuals (HRI) of pancreatic cancer, focusing on genetic risk factors. In the early recruitment period of 3 years from May 2020 to March 2022, the PRECEDE gathered analysis-eligible data on 1,113 HRIs. In this issue of Cancer Prevention Research, Katona and colleagues reported current portrait of demographics of the participants, with significant disparities in gender, race and ethnicity. Now the PRECEDE Consortium aims at correcting these disparities in the next 3 years and double the percentage of underrepresented groups to more closely represent the demographics of patients. See related article by Katona et al., p. 343.